About GeneLeap

Geneleap is a subsidiary of Luye, which is committed to the development of gene and nucleic acid characteristic drug technology. It was established in July 2020 and has a branch in biological Valley, Jiangbei new area, Nanjing and Boston, USA.

Focusing on the field of infectious diseases and tumor immunology, the company has an RNA (vaccine) drug development and LNP delivery technology platform, try to provide more advanced and effective clinical treatment for infectious diseases, genetic diseases and refractory tumors.

Technology

We seek to treat patient populations with urgent unmet needs, who currently have no available therapies to modify the progressive course of their disease.

Gene Therapy

The goal of gene therapy is to treat or possibly prevent disease. Scientists have been investigating and evolving gene therapy for more than 50 years. One goal of gene therapy research is to determine whether a new or functional gene can be used to restore the function of, or inactivate, a mutated gene.

Our Science

At GeneLeap Biotech, we develop highly innovative drugs based on synthetic modified messenger RNA (mRNA). These mRNAs encode virtually any conceivable natural or engineered protein and are designed to be taken up by the cells in specific tissues and organs. We focus on diseases wherein enabling targeted cells to produce – or turn ‘on’ – one or more proteins helping the body to fight or prevent disease.

we are expanding the use of adeno-associated viral (AAV) vectors against strategically selected cell targets, including the retina, liver, and central nervous system. Additionally, we are actively advancing the development of oligonucleotide-based TLR9 agonists for immune-oncology applications allows reduced dosing frequency with improved efficacy for cancer patients with unmet medical needs distinguishing from the current treatments in the clinic.

About GeneLeap

Technology

Gene Therapy

Our Science

MRNA Programs